The HSPA1A Knockout HEK293T Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population with disruption of the human HSPA1A gene. This loss-of-function model enables systematic study of the stress-inducible Hsp70 chaperone in protein homeostasis and cell survival. The polyclonal format provides a robust genetic background for functional analyses without the biases of clonal selection.
HEK293T cells are human embryonic kidney epithelial cells transformed with SV40 large T antigen, facilitating high-level protein expression and viral production. Their extensive use in signaling and cancer research makes them an ideal host for dissecting HSPA1A-dependent pathways. The knockout background offers a clean system to explore chaperone-mediated stress responses in a well-characterized cellular context.
HSPA1A is transcriptionally regulated by HSF1 in response to heat shock and other proteotoxic conditions. The encoded Hsp70 protein orchestrates protein folding and quality control, functionally cooperating with co-chaperones like DNAJB1, BAG1, and STUB1. Crucially, Hsp70 binds Apaf-1 to block apoptosome formation and modulates JNK signaling to suppress Bcl-2-regulated apoptosis, thereby linking the heat shock response to MAPK and NF-kappa B pathways.
Disruption of HSPA1A in HEK293T cells removes this cytoprotective mechanism, sensitizing cells to stress-induced death and promoting protein aggregation. This phenotype is relevant for modeling neurodegenerative diseases and ischemia-reperfusion injury, and for testing the dependency of cancer cells on Hsp70 for survival. The knockout cells thus serve as a platform for mechanistic studies and drug development.
Applications include monitoring apoptosis via caspase-3 assays and annexin V staining, assessing aggregation with immunofluorescence, and evaluating drug sensitivity using Hsp70 inhibitors such as VER-155008. Co-immunoprecipitation studies can delineate Hsp70 interaction networks. These cells are valuable for target validation in oncology and neuroprotection. For further inquiries, please contact Ascent Research.
